Neurocrine Biosciences INC (NBIX) Shareholder Fosun International LTD Upped Position

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) LogoInvestors sentiment increased to 1.44 in 2019 Q1. Its up 0.45, from 0.99 in 2018Q4. It is positive, as 37 investors sold NBIX shares while 71 reduced holdings. 45 funds opened positions while 110 raised stakes. 101.77 million shares or 17.27% more from 86.79 million shares in 2018Q4 were reported. Tower Rech Capital Lc (Trc) has invested 0% in Neurocrine Biosciences, Inc. (NASDAQ:NBIX). Geode Capital Ltd Liability Corp owns 0.02% invested in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) for 949,129 shares. Navellier And Assoc Inc invested in 0.28% or 20,764 shares. Trexquant LP invested in 0.13% or 21,445 shares. Royal Commercial Bank Of Canada holds 24,054 shares or 0% of its portfolio. State Of Alaska Department Of Revenue holds 10,502 shares. Mackenzie Fincl holds 0% or 8,694 shares in its portfolio. Principal Group Incorporated owns 54,195 shares. 100 are held by Reilly Fincl Advsrs Limited Liability Corp. Thrivent For Lutherans invested in 185,607 shares. Bnp Paribas Asset Mngmt Sa owns 366,879 shares or 0.27% of their US portfolio. Asset One reported 0.01% in Neurocrine Biosciences, Inc. (NASDAQ:NBIX). Rice Hall James & Assoc Limited Liability Corporation accumulated 73,724 shares. Oakbrook Invs Limited Liability Company holds 2,500 shares. Point72 Asset Lp holds 388,692 shares.

Fosun International Ltd increased its stake in Neurocrine Biosciences Inc (NBIX) by 62.58% based on its latest 2019Q1 regulatory filing with the SEC. Fosun International Ltd bought 39,000 shares as the company’s stock rose 29.28% . The institutional investor held 101,323 shares of the health care company at the end of 2019Q1, valued at $8.67M, up from 62,323 at the end of the previous reported quarter. Fosun International Ltd who had been investing in Neurocrine Biosciences Inc for a number of months, seems to be bullish on the $8.69B market cap company. The stock increased 0.53% or $0.5 during the last trading session, reaching $94.88. About 483,284 shares traded. Neurocrine Biosciences, Inc. (NASDAQ:NBIX) has declined 2.64% since August 15, 2018 and is downtrending. It has underperformed by 2.64% the S&P500.

Fosun International Ltd, which manages about $1.57B US Long portfolio, decreased its stake in Alphabet Inc by 7,515 shares to 4,735 shares, valued at $5.55 million in 2019Q1, according to the filing. It also reduced its holding in Yy Inc (NASDAQ:YY) by 56,151 shares in the quarter, leaving it with 3,649 shares, and cut its stake in Cowen Inc.

More notable recent Neurocrine Biosciences, Inc. (NASDAQ:NBIX) news were published by: Nasdaq.com which released: “Achillion (ACHN) Reports Wider Y/Y Loss in Q2, Revenues Nil – Nasdaq” on August 09, 2019, also Seekingalpha.com with their article: “Baird sees 37% upside in Regeneron in premarket analyst action – Seeking Alpha” published on August 07, 2019, Nasdaq.com published: “First Week of April 18th Options Trading For Neurocrine Biosciences (NBIX) – Nasdaq” on March 07, 2019. More interesting news about Neurocrine Biosciences, Inc. (NASDAQ:NBIX) were released by: Nasdaq.com and their article: “Should You Buy Neurocrine (NBIX) Ahead of Earnings? – Nasdaq” published on July 26, 2019 as well as Streetinsider.com‘s news article titled: “After-Hours Movers 07/29: (LXU) (RNG) (NBIX) Higher; (MDR) (SSNC) (BYND) (more…) – StreetInsider.com” with publication date: July 29, 2019.

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Ratings Coverage

Among 8 analysts covering Neurocrine (NASDAQ:NBIX), 7 have Buy rating, 0 Sell and 1 Hold. Therefore 88% are positive. Neurocrine has $127 highest and $87 lowest target. $108.25’s average target is 14.09% above currents $94.88 stock price. Neurocrine had 15 analyst reports since March 12, 2019 according to SRatingsIntel. Leerink Swann maintained it with “Hold” rating and $87 target in Tuesday, March 12 report. The stock has “Overweight” rating by JP Morgan on Monday, April 22. The stock of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) has “Outperform” rating given on Tuesday, July 30 by Credit Suisse. Cantor Fitzgerald maintained the stock with “Buy” rating in Tuesday, March 12 report. The rating was maintained by Piper Jaffray with “Overweight” on Tuesday, July 30. The company was maintained on Wednesday, March 13 by H.C. Wainwright. The stock of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) earned “Buy” rating by Cowen & Co on Wednesday, March 13.

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.